Covid-19 roundup: CanSino’s inhaled vaccine gets thumbs-up from Chinese regulators; Sinovac gets go-ahead for booster trial in Chile

06 Sep 2022
endpts.com
VaccineCollaborateAntibody
While the world has been focused on injectable booster shots to address the Omicron variant, one company focused on a different approach has seen its product take a major step forward. Chinese biotech CanSino Biologics has received approval from the National Medical Products Administration of China for its inhaled Covid-19 vaccineCovid-19 vaccine, dubbed Convidecia Air, to be used as a booster. The company said that its booster uses an adenovirus vector platform and it touted the non-invasive nature of the vaccine, as compared to injectable jabs already on the market. The booster dose uses a nebulizer to change liquid into an aerosol so it can be inhaled via the mouth. CanSino initially received approval for its spray vaccine last year as it presented the vaccine’s effectiveness in The Lancet, along with several experts giving the spray a positive review . The Lancet’s report on Phase II of the vaccine in 2021 showed that it had induced over 85% of volunteers to create antibodies for the novel coronavirus and a T-cell response within 14 days of receiving the vaccine. There were also no serious adverse events reported. While the approval is good news for CanSino, it needs a pick me up as the company has been staring down an 82% drop in its stock price since September of last year. As booster vaccines to counter the Omicron variant are beginning to roll out, other biotechs are not giving up the ship in presenting results for its candidates. Clover Biotherapeutics on Tuesday presented data from its Phase III trial for its vaccine candidate SCB-2019, as a universal booster for the virus. The data from its study, which was conducted in the Philippines, showed that a booster dose of SCB-2019 in participants who had received two doses of the inactivated vaccine did have an immune response against both the original strain as well as the Omicron variants BA.1 and BA.2. Patients with low pre-booster antibody levels showed that the booster candidate gave a 17-fold increase in antibodies against the original strain, with the geometric mean titers (GMT) of antibodies increasing from 44 to 733. The booster also had a 6-fold increase in antibodies against BA.1 and an 8-fold boost against BA.2. However, no results were given against the BA.5 variant. According to the company, those data are expected to be released soon, but no timeline was given. The company is also looking to enroll a cohort to investigate the effects of a fourth dose of the booster candidate, as well. While Sinovac has hit stumbling blocks in South America previously — with Brazil halting over 12 million doses last year after its manufacturing site was not approved for emergency use — the company is going ahead with a clinical trial in another country on the continent. The Chilean Public Health Institute has given the Chinese pharma the go-ahead to conduct a Phase II trial for its Omicron strain Covid-19 vaccine and trivalent vaccine, which is designed to counter the original strain as well as all Delta and Omicron variants, the company announced on Tuesday. The trial will evaluate the safety and immunogenicity of one booster dose of the two candidates in adults who have already received two vaccine doses, the company said. The double-blind Phase II aims to enroll 826 patients.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.